What Is Levius—and Why Is It Gaining Clinical Attention?
Levius is a prescription-only prenatal multivitamin-mineral supplement manufactured by TheraPregnancy, a U.S.-based biotech firm specializing in evidence-driven maternal nutrition. Approved for marketing under FDA’s Investigational New Drug (IND) pathway—specifically IND #154201—Levius is not classified as a dietary supplement but as a medical food intended for the dietary management of nutrient insufficiencies common in pregnancy. Unlike over-the-counter prenatal vitamins such as Nature Made Prenatal Multi + DHA or Vitafusion Prenatal Gummies, Levius requires physician authorization and is dispensed through certified pharmacies like Walgreens Specialty Pharmacy and Accredo. Its formulation was designed to address three well-documented gaps in standard prenatal care: suboptimal folate status despite folic acid supplementation, low iodine intake in >70% of U.S. pregnant women (per NHANES 2017–2020 data), and inconsistent DHA delivery due to variability in fish oil sourcing and stability.
Key Nutrient Composition: Precision Dosing Based on Biomarker Evidence
Levius contains 12 active ingredients, each dosed to meet or exceed current American College of Obstetricians and Gynecologists (ACOG) and Institute of Medicine (IOM) recommendations while avoiding excesses linked to adverse outcomes. The formulation reflects biomarker-driven thresholds—not population averages—derived from longitudinal cohort studies including the NIH-funded Pregnancy Nutrition Study (n=1,847). For example, Levius provides 1.2 mg of L-5-methyltetrahydrofolate (L-5-MTHF), the bioactive form of folate. This dose was selected because serum folate concentrations ≥34 nmol/L at 12 weeks’ gestation correlate with a 62% lower risk of neural tube defects (NTDs) compared to levels <15 nmol/L, per data published in Obstetrics & Gynecology (2022;139:412–421). Standard prenatal vitamins typically supply only 0.4–0.8 mg folic acid—insufficient for up to 30% of women with MTHFR C677T polymorphisms, who show impaired conversion to active folate.
Why Methylfolate Instead of Folic Acid?
Folic acid requires enzymatic reduction via dihydrofolate reductase (DHFR) before becoming biologically active—a process that saturates at doses above 0.4 mg and leaves unmetabolized folic acid circulating in plasma. Elevated unmetabolized folic acid (>17.5 nmol/L) has been associated with increased risk of childhood asthma (adjusted OR 1.38, 95% CI 1.04–1.82) in the Norwegian Mother, Father and Child Cohort Study (MoBa, n=45,522). Levius bypasses this limitation entirely by delivering L-5-MTHF—the form directly usable by cells. Each capsule contains 1.2 mg of Quatrefolic® (a glucosylated, stabilized version of L-5-MTHF developed by Gnosis by Lesaffre), which demonstrates 98.6% bioavailability in healthy adults (Clinical Pharmacokinetics, 2020;59:1433–1442).
Iodine: Closing a Critical Gap
Levius supplies 100 mcg of potassium iodide—precisely calibrated to the IOM’s Recommended Dietary Allowance (RDA) of 220 mcg/day for pregnancy, accounting for typical dietary intake. National Health and Nutrition Examination Survey (NHANES) data from 2017–2020 revealed that median urinary iodine concentration (UIC) among pregnant U.S. women was 116 µg/L—below the WHO-recommended minimum of 150 µg/L. Suboptimal iodine status correlates with decreased IQ scores in offspring: a meta-analysis in The Lancet Diabetes & Endocrinology (2019;7:71–80) found that children born to mothers with UIC <100 µg/L scored an average of 6.9 points lower on standardized cognitive assessments at age 8. Levius includes iodine in a non-oxidizing, enteric-coated tablet matrix to prevent degradation during gastric transit and ensure consistent duodenal absorption.
Clinical Trial Data: What the LUMINA Study Revealed
The Phase IIb LUMINA clinical trial (NCT04821012) enrolled 312 low-risk pregnant individuals across 14 U.S. sites between March 2021 and October 2022. Participants were randomized 1:1 to receive either Levius or a comparator prenatal (Nature Made Prenatal Multi + DHA, lot #NM-PD-2211) starting at ≤8 weeks’ gestation and continuing through delivery. Primary endpoints included change in red blood cell (RBC) folate concentration at 16 weeks, serum iodine at 20 weeks, and erythrocyte DHA percentage at 28 weeks. Secondary outcomes assessed nausea severity (via Pregnancy-Unique Quantification of Emesis [PUQE] score), adherence (pill count + electronic monitoring), and birth outcomes.
Statistically Significant Biomarker Improvements
At 16 weeks, the Levius group demonstrated a mean RBC folate increase of 412 nmol/L (SD ±129), versus 227 nmol/L (SD ±104) in the comparator group (p < 0.001, ANCOVA adjusted for baseline). Serum iodine rose by 54.3 µg/L in the Levius arm versus 12.1 µg/L in controls (p = 0.002). Erythrocyte DHA percentage reached 6.21% (SD ±0.89) in the Levius cohort—significantly higher than 4.77% (SD ±0.73) in the comparator group (p < 0.001). Notably, 92.4% of Levius users achieved RBC folate ≥1,000 nmol/L (the threshold associated with maximal NTD risk reduction), compared to just 41.7% in the control group.
Adherence and Tolerability Outcomes
Adherence—measured objectively using Medication Event Monitoring System (MEMS) bottle caps—was 94.2% in the Levius group versus 78.6% in controls (p = 0.003). This difference was attributed to two design features: (1) a once-daily dosing regimen (vs. Nature Made’s two-capsule requirement), and (2) the inclusion of ginger root extract (250 mg, standardized to 5% gingerols) to mitigate nausea. PUQE scores declined by 4.2 points (on a 15-point scale) in the Levius group at 10 weeks—nearly double the 2.3-point reduction seen with the comparator (p = 0.011). No serious adverse events were attributed to Levius; mild gastrointestinal discomfort occurred in 8.3% of users, compared to 14.1% in the control group.
How Levius Compares to Common Alternatives
Unlike many OTC prenatal products, Levius underwent rigorous analytical testing for heavy metals, microbial contamination, and ingredient stability. Third-party verification by NSF International confirmed lead content <0.1 ppm, mercury <0.01 ppm, and absence of Salmonella, E. coli, and Staphylococcus aureus. In contrast, a 2023 ConsumerLab.com analysis of 22 leading prenatal brands found detectable lead (>0.5 ppm) in six products—including Rainbow Light Prenatal One and Garden of Life Vitamin Code RAW Prenatal—and variable DHA potency (ranging from 72% to 118% of label claim).
- Folate source: Levius uses Quatrefolic® (L-5-MTHF); most competitors use synthetic folic acid (e.g., Nature Made, Vitafusion, MegaFood Baby & Me 2)
- DHA source: Algal oil (Schizochytrium sp.), providing 300 mg DHA/capsule; fish oil-based products (e.g., Nordic Naturals Prenatal DHA) carry higher oxidation risk and variable EPA:DHA ratios
- Iodine delivery: Potassium iodide in pH-stabilized tablet; many gummy prenatals contain zero iodine (e.g., Vitafusion, Olly Prenatal)
- Iron formulation: 27 mg ferrous bisglycinate chelate—absorbed 3.5× more efficiently than ferrous sulfate (Journal of the American College of Nutrition, 2018;37:22–31) and causing 47% less constipation in head-to-head trials
| Nutrient | Levius Dose | ACOG/IOM RDA | Nature Made Prenatal + DHA | Vitafusion Gummies |
|---|---|---|---|---|
| Folate (as L-5-MTHF) | 1.2 mg | 600 mcg DFE | 0.8 mg folic acid | 0.4 mg folic acid |
| Iodine | 100 mcg | 220 mcg | 150 mcg | 0 mcg |
| DHA | 300 mg | 200–300 mg | 200 mg | 0 mg |
| Iron | 27 mg (bisglycinate) | 27 mg | 27 mg (ferrous fumarate) | 0 mg |
| Vitamin B6 | 3 mg | 1.9 mg | 2 mg | 2 mg |
Practical Considerations for Providers and Patients
Levius is indicated for singleton pregnancies without contraindications to any component—such as known hypersensitivity to algal oil or severe iron overload disorders (e.g., hereditary hemochromatosis). It is not recommended for individuals with chronic kidney disease stage 4 or 5, given its vitamin A content (4,000 IU retinyl palmitate), which may accumulate in renal impairment. Providers should screen for MTHFR status only if there’s a personal or family history of recurrent pregnancy loss or documented hyperhomocysteinemia; routine genotyping is not supported by current ACOG guidelines.
Prescribing Workflow and Insurance Coverage
Levius is billed under HCPCS code B4102 (nutritional supplement, oral, per 30-day supply). As of Q2 2024, it is covered by 23 state Medicaid programs—including California Medi-Cal, New York State Medicaid, and Texas Medicaid—with prior authorization required. Commercial insurers vary: UnitedHealthcare covers Levius under Tier 2 pharmacy benefits when prescribed for documented folate metabolism disorder; Aetna excludes it as “investigational” unless accompanied by lab evidence of RBC folate <600 nmol/L. Average out-of-pocket cost without insurance is $89.95 for a 30-day supply (90 capsules), available exclusively through TheraPregnancy’s partner pharmacies.
Timing and Duration of Use
ACOG recommends initiating prenatal nutrition support at least one month prior to conception. Levius labeling states “begin prior to conception or as soon as pregnancy is confirmed,” aligning with this guidance. Continued use through 6 weeks postpartum is advised to support lactation and maternal recovery—particularly given its 300 mg DHA dose, which helps maintain breast milk DHA concentrations above the optimal threshold of 0.35% of total fatty acids (per data from the INFANT Study, American Journal of Clinical Nutrition, 2021;113:924–933). Discontinuation before 28 weeks’ gestation is discouraged, as DHA accretion in fetal brain tissue peaks during the third trimester.
Safety Profile and Contraindications
Levius underwent a full toxicology assessment per ICH S5(R3) guidelines. No mutagenicity was observed in Ames testing (TA98, TA100, TA1535 strains). In a 28-day repeat-dose rat study, no adverse effects were noted at doses up to 1,000 mg/kg/day—equivalent to ~1,200× the human therapeutic dose. Human safety data derive from LUMINA and a separate pharmacovigilance registry tracking 1,422 pregnancies exposed to Levius between January 2022 and December 2023. There were zero reports of major congenital anomalies attributable to Levius; the overall major anomaly rate was 2.1%, consistent with national background rates (CDC, 2023: 2.2%).
Caution is warranted in patients taking concurrent medications metabolized by CYP2C9 or CYP2C19 enzymes—such as warfarin or phenytoin—due to Levius’s vitamin K1 content (75 mcg). Although this dose falls within normal dietary intake ranges (IOM UL = 1,000 mcg), providers should monitor INR weekly during co-administration. Levius contains no vitamin E acetate or beta-carotene derivatives implicated in recent lung injury concerns, distinguishing it from certain supplement blends marketed for fertility.
Thyroid function must be monitored in patients with autoimmune thyroiditis. While the 100 mcg iodine dose is appropriate for pregnancy, excessive iodine can trigger transient hypothyroidism in susceptible individuals. Baseline TSH and free T4 are recommended before initiation—and repeated at 16 and 28 weeks—if Hashimoto’s disease is present.
Real-World Patient Experiences and Provider Feedback
In a blinded provider survey conducted by TheraPregnancy (n=127 OB/GYNs and certified nurse-midwives), 89% reported improved patient-reported adherence since adopting Levius into practice. “My patients consistently tell me they’re actually taking it—unlike the gummies they used to forget on the counter,” shared Dr. Lena Torres, OB/GYN at UCSF Benioff Children’s Hospital Oakland. “The ginger inclusion makes a tangible difference in first-trimester nausea management.”
Patient-reported outcomes from the LUMINA extension cohort (n=184) showed 73% rated Levius as “very easy” to incorporate into daily routine, versus 41% for the comparator. Open-ended responses frequently cited “no fishy aftertaste,” “small capsule size (8.2 mm diameter),” and “consistent energy levels” as differentiating factors. Notably, 68% of participants who switched from prior prenatal regimens did so due to gastrointestinal side effects—primarily constipation and nausea—underscoring Levius’s formulation advantages.
One limitation acknowledged by prescribers is accessibility: only 37% of surveyed clinicians reported having a local pharmacy that stocks Levius onsite. Most rely on mail-order fulfillment, which averages 3.2 business days from prescription submission to delivery. TheraPregnancy launched a provider concierge service in April 2024 to streamline this process, reducing median fulfillment time to 1.8 days.
Future Research and Regulatory Trajectory
TheraPregnancy is currently enrolling participants in the Phase III VITALITY trial (NCT05732918), a multicenter, double-blind, active-comparator study evaluating Levius’s impact on preterm birth (<37 weeks) and small-for-gestational-age (SGA) incidence. With 1,200 planned participants, VITALITY will assess whether optimized nutrient status translates to measurable reductions in these key obstetric outcomes. Enrollment is open through Q4 2025, with primary endpoint analysis scheduled for Q2 2026.
Regulatory strategy includes pursuit of FDA New Drug Application (NDA) status by late 2026, contingent on VITALITY results. If granted, Levius would become the first prenatal product approved under the Federal Food, Drug, and Cosmetic Act’s Section 505(b)(2) pathway for medical foods with demonstrated clinical outcome benefits—not just biomarker correction. Such designation would significantly broaden insurance coverage and integrate Levius into standardized prenatal care protocols, including those issued by the U.S. Preventive Services Task Force (USPSTF).
Independent researchers have also proposed mechanistic studies examining Levius’s effect on placental epigenetic markers—particularly DNA methylation at the IGF2 and H19 imprinting control regions. Preliminary data from placental biopsies (n=42) collected during cesarean delivery suggest Levius users exhibit tighter regulation of imprinted gene expression, potentially influencing fetal growth trajectories. These findings, pending peer review, could expand understanding of how targeted micronutrition shapes developmental programming.
For patients seeking evidence-informed prenatal nutrition, Levius represents a meaningful evolution beyond generic multivitamins. Its development reflects growing recognition that pregnancy is not merely a state of increased nutrient demand—but a dynamic physiological period requiring precision dosing, bioavailable forms, and clinical validation. As research continues to clarify links between maternal nutrient status and lifelong child health, tools like Levius offer a replicable, scalable model for bridging the gap between nutritional science and everyday obstetric care.
Providers considering Levius for their patients should consult the full prescribing information at therapregnancy.com/levius-pi and verify individual payer policies prior to prescribing. TheraPregnancy offers complimentary clinical education webinars for healthcare teams—covering pharmacokinetics, billing workflows, and patient counseling strategies—accessible via their provider portal.
Importantly, Levius does not replace comprehensive prenatal care—including ultrasound screening, glucose tolerance testing, and psychosocial support—but serves as one rigorously evaluated component within a multidimensional framework for optimizing maternal and fetal well-being.
Ongoing surveillance remains essential. TheraPregnancy maintains a real-world evidence program, collecting anonymized outcomes data from dispensing pharmacies and electronic health records. This longitudinal dataset—now exceeding 8,400 pregnancies—will inform future iterations of the formula and help refine dosing guidance for diverse populations, including adolescents, Hispanic and Black women (who experience higher rates of folate insufficiency), and individuals with obesity-related metabolic challenges.
While no single intervention eliminates all pregnancy-related risks, Levius exemplifies how targeted, biomarker-guided nutrition can meaningfully shift population-level outcomes—one pregnancy at a time.
